We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+31.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$422M
AUM Growth
+$153M
Cap. Flow
+$112M
Cap. Flow %
26.56%
Top 10 Hldgs %
59.67%
Holding
84
New
36
Increased
11
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.63M
2
TSRO
TESARO, Inc.
TSRO
+$5.7M
3
VIVE
VIVEVE MED INC
VIVE
+$5.55M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.36M
5
ZGNX
Zogenix, Inc.
ZGNX
+$4.43M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$21.3M
2
AKBA icon
Akebia Therapeutics
AKBA
+$7.28M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.35M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.98M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBVT
51
CALL
DBV Technologies
DBVT
$804M
$1.06M 0.25%
+3,000
New +$1.05M
ARAV
52
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.05M 0.25%
+8,183
New +$863K
ABCO
53
DELISTED
Advisory Board Co
ABCO
$997K 0.24%
+21,300
New +$940K
XBIT icon
54
CALL
XBiotech
XBIT
$68.1M
$989K 0.23%
+60,000
New +$785K
PGNX
55
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$944K 0.22%
+100,000
New +$998K
RMTI icon
56
PUT
Rockwell Medical
RMTI
$28.5M
$876K 0.21%
1,273
– –
CNCE
57
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$837K 0.2%
+49,051
New +$588K
NVTA
58
PUT
DELISTED
Invitae Corporation
NVTA
$774K 0.18%
+70,000
New +$672K
AEHR icon
59
Aehr Test Systems
AEHR
$2.99B
$587K 0.14%
+122,000
New +$459K
NVTA
60
CALL
DELISTED
Invitae Corporation
NVTA
$553K 0.13%
+50,000
New +$480K
OMER icon
61
CALL
Omeros
OMER
$909M
$454K 0.11%
+30,000
New +$328K
XBIT icon
62
PUT
XBiotech
XBIT
$68.1M
$330K 0.08%
+20,000
New +$262K
IOVA icon
63
CALL
Iovance Biotherapeutics
IOVA
$1.93B
$298K 0.07%
40,000
-110,000
-73% -$806K
QTNT
64
DELISTED
Quotient Limited Ordinary Shares
QTNT
$132K 0.03%
+473
New +$121K
OTLK icon
65
Outlook Therapeutics
OTLK
$171M
$78K 0.02%
182
– –
ONSIW
66
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$77K 0.02%
96,833
– –
ONSIZ
67
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$48K 0.01%
96,833
– –
AKBA icon
68
Akebia Therapeutics
AKBA
$351M
– –
-698,825
Closed -$7.28M
ARDX icon
69
Ardelyx
ARDX
$1.23B
– –
-26,891
Closed -$382K
EXEL icon
70
PUT
Exelixis
EXEL
$13.8B
– –
-80,000
Closed -$1.19M
FOLD
71
DELISTED
Amicus Therapeutics
FOLD
– –
-145,300
Closed -$722K
MNKD icon
72
PUT
MannKind Corp
MNKD
$1.17B
– –
-18,000
Closed -$58K
PLUR icon
73
PUT
Pluri
PLUR
$17M
– –
-264
Closed -$30K
SRPT icon
74
PUT
Sarepta Therapeutics
SRPT
$1.68B
– –
-50,000
Closed -$1.37M
VNDA icon
75
Vanda Pharmaceuticals
VNDA
$315M
– –
-162,600
Closed -$2.59M
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Acuta Capital Partners held 84 positions worth $422M, up 57% from $269M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners deployed $112M of net new capital in Q1 2017, opening 36 new positions and adding to 11 existing holdings. Its largest new stake was TESARO, Inc.: 35,000 shares worth $5.38M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 77% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $21.3M trimmed.

  • Acuta Capital Partners's largest Q1 2017 buy was TESARO, Inc.: 35,000 shares worth $5.38M.
  • Acuta Capital Partners added most to Acadia Pharmaceuticals in Q1 2017, an estimated $9.63M increase.
  • Acuta Capital Partners's biggest Q1 2017 reduction was Immunomedics Inc, cutting an estimated $21.3M.
  • Acuta Capital Partners fully exited Akebia Therapeutics in Q1 2017, selling an estimated $7.28M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $422M portfolio in Q1 2017.
  • Acuta Capital Partners opened 36 new positions and closed 17 in Q1 2017.
  • Acuta Capital Partners's portfolio value rose 57% quarter-over-quarter to $422M.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.